Impact Of low phosphorus containing formula On Parathyroid Hormone Level In Children On Dialysis

Abstract

Background: Children with end-stage renal disease (ESRD) undergoing dialysis often suffer from disturbances in mineral metabolism, particularly involving calcium, phosphorus, and parathyroid hormone (PTH). One of the most common complications is secondary hyperparathyroidism (SHPT), a condition driven by phosphate retention, hypocalcemia, and reduced calcitriol synthesis, leading to increased PTH secretion. Low-phosphorus containing formulas have emerged as an important nutritional strategy to reduce serum phosphate levels and, consequently, PTH levels. So we aimed to assess the effect of low phosphorus containing formula on parathyroid hormone level in children on dialysis.

Methods: This one- arm clinical trial was conducted at Pediatrics department, Dialysis unit, Zagazig University Hospitals, Sharqia governorate, Egypt on Children on dialysis. Parathyroid hormone level assessment was done before and after taking of low phosphorus containing formula.

Results: There was a significant decrease in parathyroid hormone (PTH) levels following low phosphorus-containing formula (p<0.001) with a 95% confidence interval for the difference ranging from 80.14 to 199.59 pg/mL. 

Conclusion: The administration of a low phosphorus-containing formula in children on dialysis resulted in a statistically significant reduction in serum parathyroid hormone (PTH) and phosphorus levels, indicating its effectiveness in managing secondary hyperparathyroidism and hyperphosphatemia in this population.